Psoralens are regularly used in
therapy in combination with ultraviolet A light irradiation (PUVA) to treat
skin diseases such as
psoriasis,
vitiligo, and
mycosis fungoides.
PUVA therapy is also used within the scope of
extracorporeal photopheresis to treat a variety of diseases that have a suspected involvement of pathogenic T cells, including rejection of organ transplants,
graft-vs-host disease,
cutaneous T cell lymphoma, and autoimmune disorders. Because
psoralens are the only
photosensitizers used in
PUVA therapies and are considered to be responsible for a number of side effects, the identification of alternative drugs is of practical interest. Here we investigated the impact of activated
Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), a hydrophilic
vitamin E analog lacking the phytyl tail, as an alternative photoactivatable agent with T cell cytotoxic properties. Despite the well-known antioxidative capacity of
Trolox, we found that at low UVA doses and in the presence of supraphysiological concentration of
nitrite, a natural constituent of human skin, this compound selectively enhances radical-mediated cytotoxicity toward T cells but not toward human skin fibroblasts, keratinocytes, or endothelial cells. The cytotoxic mechanism comprises a reaction of
Trolox with photo-decomposition products of
nitrite, which leads to increased
Trolox phenoxyl radical formation, increased intracellular oxidative stress, and a consecutive induction of apoptosis and
necrosis in fast proliferating T cells. Thus, the identified UVA/
nitrite-induced
phenoxyl radical formation provides an opportunity for a new cytotoxic
photodynamic therapy.